Over the past 3 months, 6 analysts have published their opinion on Ares Management (NYSE:ARES) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
The Lockwood Group ("Lockwood"), an industry leader in scientific-based medical communications for the pharmaceutical, biotech, and medical device industries, announced today a strategic investment made by a
Ares Management (NYSE:ARES) has outperformed the market over the past 90 days by 14.08%, generating a 13.84% return for its investors over the time period. Now, given this information, it may seem like price appreciation alone is the best way to have made money on this stock, that's not actually the case.